Marinus PharmaceuticalsMRNS
MRNS
About: Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Employees: 166
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
176% more call options, than puts
Call options by funds: $398K | Put options by funds: $144K
45% more capital invested
Capital invested by funds: $50.9M [Q2] → $73.8M (+$22.9M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.76% less ownership
Funds ownership: 79.1% [Q2] → 75.34% (-3.76%) [Q3]
16% less funds holding
Funds holding: 90 [Q2] → 76 (-14) [Q3]
26% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 27
52% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 25
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$0.50
8%
downside
Avg. target
$2.25
315%
upside
High target
$4
638%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
Cantor Fitzgerald Charles Duncan 49% 1-year accuracy 40 / 81 met price target | 638%upside $4 | Overweight Reiterated | 14 Nov 2024 |
HC Wainwright & Co. Douglas Tsao 31% 1-year accuracy 54 / 173 met price target | 269%upside $2 | Neutral Reiterated | 14 Nov 2024 |
D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target | 454%upside $3 | Buy Maintained | 13 Nov 2024 |
RBC Capital Brian Abrahams 10% 1-year accuracy 8 / 79 met price target | 85%upside $1 | Sector Perform Maintained | 25 Oct 2024 |
Jefferies Andrew Tsai 0% 1-year accuracy 0 / 5 met price target | 8%downside $0.50 | Hold Downgraded | 25 Oct 2024 |
Financial journalist opinion
Based on 5 articles about MRNS published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Business Wire
2 weeks ago
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marinus Pharmaceuticals, Inc. (NasdaqGM: MRNS) to Immedica Pharma AB. Under the terms of the proposed transaction, shareholders of Marinus will receive $0.55 in cash for each share of Marinus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
Neutral
Business Wire
3 weeks ago
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Marinus shareholders will receive $0.55 per share. Marinus insiders will receive substantial benefits as pa.
Neutral
Business Wire
3 weeks ago
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders. Halper Sadeh encourages Marinus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Marinus an.
Neutral
Business Wire
3 weeks ago
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. The acquisition complements and further strengthens Immedica's gl.
Negative
Zacks Investment Research
2 months ago
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.
Neutral
Business Wire
2 months ago
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. “We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of.
Neutral
Business Wire
2 months ago
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency. While reductions in seizure frequency fav.
Neutral
Business Wire
3 months ago
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June.
Positive
Benzinga
3 months ago
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.
Charts implemented using Lightweight Charts™